Difference between revisions of "Eribulin (Halaven)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Non-taxane microtubule dynamics inhibitor. Inhibits the growth phase of microtubules and aggregates tubulin into inactive aggregates. Does not affect the shortening phase. Disruption of mitotic spindles interferes with mitosis, leads to G2/M cell-cycle block, and apoptotic cell death.<ref name="insert">[http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf Eribulin (Halaven) package insert]</ref><ref>[ | + | Class/mechanism: Non-taxane microtubule dynamics inhibitor. Inhibits the growth phase of microtubules and aggregates tubulin into inactive aggregates. Does not affect the shortening phase. Disruption of mitotic spindles interferes with mitosis, leads to G2/M cell-cycle block, and apoptotic cell death.<ref name="insert">[http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf Eribulin (Halaven) package insert]</ref><ref>[[Media:Eribulin.pdf | Eribulin (Halaven) package insert (locally hosted backup)]]</ref><ref>[http://halaven.com Halaven manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf#page=14 Eribulin (Halaven) package insert pages 14-16]<ref name="insert"></ref> | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/eribulin.aspx Eribulin (Halaven) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/eribulin.aspx Eribulin (Halaven) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/eribulin-patient-drug-information Eribulin (Halaven) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eribulin-patient-drug-information Eribulin (Halaven) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/eribulin-patient-drug-information Eribulin (Halaven) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eribulin-patient-drug-information Eribulin (Halaven) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Microtubule inhibitors]] | ||
| + | [[Category:Breast cancer medications]] | ||
Revision as of 06:46, 16 October 2012
General information
Class/mechanism: Non-taxane microtubule dynamics inhibitor. Inhibits the growth phase of microtubules and aggregates tubulin into inactive aggregates. Does not affect the shortening phase. Disruption of mitotic spindles interferes with mitosis, leads to G2/M cell-cycle block, and apoptotic cell death.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Eribulin (Halaven) package insert pages 14-16[1]
- Eribulin (Halaven) patient drug information (Chemocare)[4]
- Eribulin (Halaven) patient drug information (UpToDate)[5]